Featured Insights
March 26, 2018
“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER
The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. The credibility afforded by ICER’s independent status, and its inclusion of diverse stakeholder views in constructing its cost effectiveness analyses, are leading payers and PBMs to use the analyses to establish coverage criteria, determine formulary placement and negotiate discounts from drug manufacturers.
read full insight article >
February 20, 2018
Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract
Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.
read full press release >
January 11, 2018
Ophthalmology Innovation Summit
Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves
Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.
Listen to full insight podcast >
May 16, 2017
BioCentury
Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals
Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.
Read full insight article >
May 3, 2017
Real Endpoints' White Paper
Preferences in MS Therapy: White Paper and Literature Review
Real Endpoints, LLC (RE), a data and analytics firm that assesses and quantifies pharmaceutical value, just published a white paper and extensive literature review to tease out how different stakeholder groups (patients, payers and physicians) assess the value of current multiple sclerosis (MS) therapies.
Read full insight paper > Key Findings, Preferences in MS Therapy >
July 31, 2016
In Vivo
Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace
As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.
Read full insight article >Insights
October 10, 2016
Talk at the Top Podcast
Roger Longman on the Drug Pricing War
Roger Longman speaks about drug pricing in the current environment, and how payers, pharma, and providers must adapt to ever-changing models of reimbursement.
Listen to the full insight interview >
July 18, 2016
In Vivo
The Value Lab: Moving Value-Based Health Care from Theory to Practice
A new, structured approach to bringing value-based reimbursement models into the mainstream is outlined, thus transforming reimbursement and fueling the shift from volume to value.
Read full insight article >
January 13, 2016
NEJM Catalyst
Who Has the Power to Cut Drug Prices?
Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
Read full insight article >
January 1, 2016
Ernst & Young
The “Myth” of the Payer
Not all payers make their decisions the same way. Smart payer segmentation strategies are extremely important to successful biopharmas.
Read full insight article >
December 1, 2015
Harvard Business Review
Who Has the Power to Cut Drug Prices? Employers.
Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
Read full insight article >
November 12, 2015
Journal of Clinical Pathways Viewpoints
Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of resistance from drug companies and payers, stakeholders are finding other tools to help identify the appropriate choices.
Read full insight article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.